-
According to the article, the cost is more and you may not feel the customary “puff” as much with the new devices. The new devices tend to clog easier. The reason for the change, the ozone and chlorofluorocarbon that damage, so even the asthma inhalers are going green, not literally I think...
-
This is the second approval this week for a generic version of Wellbutrin, earlier this week Watson Pharmaceuticals announced it’s new version. BD The Food and Drug Administration approved a generic copy of an antidepressant made by Impax Laboratories Inc. Regulators gave the drug — a copy of GlaxoSmithKline...
-
If you are one of many, well like all of us in the search for information relative to healthcare today, the self diagnosing trends are alive and well. With the wealth of information we have available, it is easy to do a little reading and self diagnose yourself with an entire multitude of diseases...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-30-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, Microsoft/Windows News, healthcare, microsoft, Medical Records, PHR, Personal Health Records, HealthVault, Data Mining, Diagnosis, ER, distractions, primary MD, cyberchondria
-
Lawmakers are going to have a difficult time with this one as they are not technically up to date enough as a whole to comprehend how all of this works in my estimation. with understanding the algorithms of finance and the economy, Wall Street showed us that. Sad, but it is true and this...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-28-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, healthcare, privacy, health insurance, Prescriptions, Congress, Hospitals, Blue Cross, Blue Shield, Venture Capital, Reserve Funds, Profits
-
Teva Pharma has a generic version, but earlier this year there were some consumer complaints, now the FDA has cleared another manufacturer to produce a generic version, Watson Pharmaceuticals. This is for the 150 mg dose. No word yet as to the availability from the article. ...
-
The entire focus is to see whether or not patent laws have been violated and if less expensive generics were in any way stalled from getting to the market place. It all boils down to intellectual-property rights and patient disputes. Interesting that Teva is settling lawsuits and will be...
-
The software, Virtual Touch Tissue Quantification, is the first and only application to provide a numerical value related to tissue stiffness at a precise anatomical location. It is not yet available or approved by the FDA for use in the US, but is pending a 501 (k) approval. The unit...
-
Current economic conditions are taking their toll on the biotech industry. Both companies are involved in research and development for cancer drugs and treatments. BD Exact Sciences Corp ., a Marlborough company trying to use genomics to develop cancer-screening technology, said today...
-
Some issues are a result of still being paper driven as timely reports and real time information are not available, but they are not the only government agency in this scenario, only one of the most critical though. Also, some members of Congress don’t use computers either and felt uncomfortable...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Medical Records, Pharma, FDA, Congress, integration, CMS, Leavitt
-
More investing to develop drugs to help in the battle with staph and MRSA infections. All R and D is located in in India. BD Biotech firm GangaGen, based in Palo Alto, Calif., brought in $5.4 million in fifth-round funding from ATEL Ventures, Otsuka Pharmaceuticals and ICF Ltd. to develop...
-
Hopefully this one will make it, sounds good. The build up of uric acid combined with someone that also suffers with diabetes can really create on restrictive diet for what they can eat and this could stand to treat as well as perhaps bring a little quality of life back to helping with allowing...
-
Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-25-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
-
This is a great start in this direction and it is one big task to find all the relative data to get down to perhaps even more drugs that could have off label use, something the FDA wants to be aware of since they are the agency who is there to approve and guide the citizens of the US for safe drug and...
-
Viagra, almost the everything, anything drug! When you stop and think back about how the drug came to market and the entire story, it is pretty interesting in the fact that it was initially researched as a cardio drug and not what it used for today. At any rate, if you are an athlete covered by...
-
One more story on the lack of communication between data bases here. If queries were ran and matches were determined, this would certainly help keep a lid on some of this, but as we all know the FDA is working hard to play catch up in the technology department after years of almost no growth in...